Ad26.COV2.S priming provided a solid immunological base for mRNA-based COVID-19 booster vaccination
© 2022 The Author(s)..
The emergence of novel SARS-CoV-2 variants led to the recommendation of booster vaccinations after Ad26.COV2.S priming. It was previously shown that heterologous booster vaccination induces high antibody levels, but how heterologous boosters affect other functional aspects of the immune response remained unknown. Here, we performed immunological profiling of Ad26.COV2.S-primed individuals before and after homologous or heterologous (mRNA-1273 or BNT162b2) booster. Booster vaccinations increased functional antibodies targeting ancestral SARS-CoV-2 and emerging variants. Especially heterologous booster vaccinations induced high levels of functional antibodies. In contrast, T-cell responses were similar in magnitude following homologous or heterologous booster vaccination and retained cross-reactivity towards variants. Booster vaccination led to a minimal expansion of SARS-CoV-2-specific T-cell clones and no increase in the breadth of the T-cell repertoire. In conclusion, we show that Ad26.COV2.S priming vaccination provided a solid immunological base for heterologous boosting, increasing humoral and cellular responses targeting emerging variants of concern.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
iScience - 26(2023), 1 vom: 20. Jan., Seite 105753 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Geers, Daryl [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Health sciences |
|---|
| Anmerkungen: |
Date Revised 29.12.2022 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.isci.2022.105753 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350194092 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350194092 | ||
| 003 | DE-627 | ||
| 005 | 20231226044436.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.isci.2022.105753 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1167.xml |
| 035 | |a (DE-627)NLM350194092 | ||
| 035 | |a (NLM)36507223 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Geers, Daryl |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Ad26.COV2.S priming provided a solid immunological base for mRNA-based COVID-19 booster vaccination |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 29.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2022 The Author(s). | ||
| 520 | |a The emergence of novel SARS-CoV-2 variants led to the recommendation of booster vaccinations after Ad26.COV2.S priming. It was previously shown that heterologous booster vaccination induces high antibody levels, but how heterologous boosters affect other functional aspects of the immune response remained unknown. Here, we performed immunological profiling of Ad26.COV2.S-primed individuals before and after homologous or heterologous (mRNA-1273 or BNT162b2) booster. Booster vaccinations increased functional antibodies targeting ancestral SARS-CoV-2 and emerging variants. Especially heterologous booster vaccinations induced high levels of functional antibodies. In contrast, T-cell responses were similar in magnitude following homologous or heterologous booster vaccination and retained cross-reactivity towards variants. Booster vaccination led to a minimal expansion of SARS-CoV-2-specific T-cell clones and no increase in the breadth of the T-cell repertoire. In conclusion, we show that Ad26.COV2.S priming vaccination provided a solid immunological base for heterologous boosting, increasing humoral and cellular responses targeting emerging variants of concern | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Health sciences | |
| 650 | 4 | |a immune response | |
| 650 | 4 | |a immunology | |
| 650 | 4 | |a virology | |
| 700 | 1 | |a Sablerolles, Roos S G |e verfasserin |4 aut | |
| 700 | 1 | |a van Baarle, Debbie |e verfasserin |4 aut | |
| 700 | 1 | |a Kootstra, Neeltje A |e verfasserin |4 aut | |
| 700 | 1 | |a Rietdijk, Wim J R |e verfasserin |4 aut | |
| 700 | 1 | |a Schmitz, Katharina S |e verfasserin |4 aut | |
| 700 | 1 | |a Gommers, Lennert |e verfasserin |4 aut | |
| 700 | 1 | |a Bogers, Susanne |e verfasserin |4 aut | |
| 700 | 1 | |a Nieuwkoop, Nella J |e verfasserin |4 aut | |
| 700 | 1 | |a van Dijk, Laura L A |e verfasserin |4 aut | |
| 700 | 1 | |a van Haren, Eva |e verfasserin |4 aut | |
| 700 | 1 | |a Lafeber, Melvin |e verfasserin |4 aut | |
| 700 | 1 | |a Dalm, Virgil A S H |e verfasserin |4 aut | |
| 700 | 1 | |a Goorhuis, Abraham |e verfasserin |4 aut | |
| 700 | 1 | |a Postma, Douwe F |e verfasserin |4 aut | |
| 700 | 1 | |a Visser, Leo G |e verfasserin |4 aut | |
| 700 | 1 | |a Huckriede, Anke L W |e verfasserin |4 aut | |
| 700 | 1 | |a Sette, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Grifoni, Alba |e verfasserin |4 aut | |
| 700 | 1 | |a de Swart, Rik L |e verfasserin |4 aut | |
| 700 | 1 | |a Koopmans, Marion P G |e verfasserin |4 aut | |
| 700 | 1 | |a van der Kuy, P Hugo M |e verfasserin |4 aut | |
| 700 | 1 | |a GeurtsvanKessel, Corine H |e verfasserin |4 aut | |
| 700 | 1 | |a de Vries, Rory D |e verfasserin |4 aut | |
| 700 | 0 | |a SWITCH research group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t iScience |d 2018 |g 26(2023), 1 vom: 20. Jan., Seite 105753 |w (DE-627)NLM285332627 |x 2589-0042 |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2023 |g number:1 |g day:20 |g month:01 |g pages:105753 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.isci.2022.105753 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2023 |e 1 |b 20 |c 01 |h 105753 | ||